Uterine Sarcoma Market Research Report - Global Forecast till 2023

Description:

Uterine Sarcoma Market research report, type (LMS, undifferentiated sarcoma), diagnosis (sampling & testing, imaging tests), treatment (surgery, radiation therapy, hormone therapy), end users (Hospitals, Research Organization) - global forecast till 2023

Market Scenario:

Sarcomas are the tumours of the mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine sarcoma is a rare type of cancer which starts in the muscle and supporting tissues of the uterus. Exposure to the X-rays increases the risk for uterine sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the common symptoms for the disease. Increasing prevalence of the uterine sarcoma and growing female geriatric population are the major drivers for the market growth during the forecast period, 2017-2023. In 2017, according to the American Cancer Society, 4,910 new cases of uterine sarcomas were reported in the U.S. Moreover, according to the World Bank, the female population which aged over 65 years rose from 316.27 billion to 347.25 billion in 2016. Additionally, rising healthcare expenditures and increasing awareness regarding women health is expected to boost the market growth. However, high cost of treatment and related side effects are the factors that can restrain the market growth. Chemotherapy is extensively exploited for the therapeutics of the uterine sarcoma. Some of the side effects of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and others.

The market for global uterine sarcoma is expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.

Intended Audience

- Pharmaceutical companies
- Biotechnological institutes
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers

Figure 1:- Global Uterine Sarcoma Market share, by Region
Sources: WHO, annual reports, press release, white paper, and company presentation

Segmentation

The global uterine sarcoma market is segmented on the basis of type, diagnosis, treatment, and end user.

On the basis of the type, the market is segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS), undifferentiated sarcoma, and others.

On the basis of the diagnosis, the market is categorised into sampling & testing, imaging tests, and others. The sampling & testing segmented is sub-segmented into endometrial biopsy, dilation and curettage, cystoscopy and proctoscopy, and others. The imaging tests segment is sub segmented into transvaginal ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography scan, and others.

On the basis of the treatment, the market is segmented into surgery, radiotherapy, chemotheraphy, hormone therapy, and others. The surgery segment is sub-segmented into bilateral salpingo-oophorectomy, hysterectomy, and others. The chemotherapy segment is sub-segmented into dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is sub segmented into progestins, aromatase inhibitors, and others.

On the basis of end users, the market is segmented into hospitals & clinics, academic institutes research organization, and others.

Regional Analysis

America dominates the global uterine sarcoma market owing to increasing adoption of new technologies and huge patient population. Additionally, rising healthcare expenditure and presence of a developed healthcare sector within the region fuels the market growth.

Europe is the second largest market for uterine sarcoma owing to rising research and development in healthcare sector and huge patient population. By region, Europe is divided into Western Europe and Eastern Europe. The presence of developed economies like France, Germany, Italy have made the Western Europe to lead the market within the region. On the other hand, Eastern Europe is the fastest growing region in Europe.

Asia Pacific region is also regarded to be the fastest growing market. Increasing awareness for women health and growing healthcare sector are the major drivers for the market growth within the region. Moreover, the presence of the developing countries like the India and China within the region fuels the market growth. According to the Indian Brand Equity Foundation in 2017, the Indian healthcare sector was one of the fastest growing industries in India and is expected to advance at a CAGR of 22.87% from 2015-2020.

The Middle East & Africa has the least share in the global uterine sarcoma market due to presence of poor economies and stringent government policies, especially in the African region. Majority of the market of Middle & Africa region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure by the presence of the economies like Saudi Arabia, Kuwait and Qatar within the region.

Research Methodology
Sources: WHO, annual reports, press release, white paper, and company presentation

Key players for global uterine sarcoma market

Pfizer Inc. (U.S.), Intas Pharmaceuticals Ltd. (India), FMC Corporation (U.S.), Sun Pharmaceutical Industries Ltd. (India), Johnson & Johnson Services, Inc. (U.S.), General Electric Company (U.S.), Koninklijke Philips N.V. (the Netherlands), Siemens Healthcare Private Limited (Germany), and others.

Contents:

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research
3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Uterine Sarcoma Market, by Type

6.1 Introduction

6.2 Uterine Leiomyosarcoma (LMS)

Market Estimates & Forecast, 2017 – 2023

6.3 Endometrial Stromal Sarcoma (ESS)

Market Estimates & Forecast, 2017 – 2023

6.4 Undifferentiated Sarcoma

Market Estimates & Forecast, 2017 – 2023

6.5 Others
Chapter 7. Global Uterine Sarcoma Market, by Diagnosis

7.1 Introduction

7.2 Sampling & Testing

Market Estimates & Forecast, 2017 – 2023

7.2.1 Endometrial Biopsy

7.2.2 Dilation and Curettage

7.2.3 Cystoscopy and Proctoscopy

7.2.4 Others

7.3 Imaging Tests

Market Estimates & Forecast, 2017 – 2023

7.3.1 Transvaginal Ultrasound

7.3.2 Computed Tomography

7.3.3 Magnetic Resonance Imaging

7.3.4 Positron Emission Tomography Scan

7.3.5 Others

7.4 Others

Chapter 8. Global Uterine Sarcoma Market, by Treatment

8.1 Introduction

8.2 Surgery

Market Estimates & Forecast, 2017 – 2023

8.2.1 Bilateral Salpingo-Oophorectomy

8.2.2 Hysterectomy

8.2.3 Others

8.3 Radiation Therapy

Market Estimates & Forecast, 2017 – 2023

8.4 Chemotherapy

Market Estimates & Forecast, 2017 – 2023
8.4.1 Dacarbazine

8.4.2 Docetaxel

8.4.3 Doxorubicin

8.4.4 Others

8.5 Hormone Therapy

Market Estimates & Forecast, 2017 – 2023

8.5.1 Progestins

8.5.2 Aromatase Inhibitors

8.5.3 Others

8.6 Others

Chapter 9. Global Uterine Sarcoma Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, 2017 – 2023

9.3 Academic Institutes

Market Estimates & Forecast, 2017 – 2023

9.4 Research Organization

Market Estimates & Forecast, 2017 – 2023

9.5 Others

Chapter 10. Global Uterine Sarcoma Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe
10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments
12.1 Pfizer Inc.

12.1.1 Company Overview

12.1.2 Diagnosis Overview

12.1.3 Financials

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Intas Pharmaceuticals Ltd.

12.2.1 Company Overview

12.2.2 Diagnosis Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 FMC Corporation

12.3.1 Company Overview

12.3.2 Diagnosis Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Sun Pharmaceutical Industries Ltd.

12.4.1 Company Overview

12.4.2 Diagnosis/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Johnson & Johnson Services, Inc.

12.5.1 Company Overview
12.5.2 Diagnosis Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 General Electric Company

12.6.1 Company Overview

12.6.2 Diagnosis Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Koninklijke Philips N.V.

12.7.1 Overview

12.7.2 Diagnosis Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Siemens Healthcare Private Limited

12.8.1 Overview

12.8.2 Diagnosis Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO's View Point
13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Uterine Sarcoma Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Global Uterine Sarcoma Industry Synopsis, 2017 – 2023

Table 2 Global Uterine Sarcoma Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Uterine Sarcoma Market by Region, 2017 – 2023, (USD Million)

Table 4 Global Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 5 Global Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)

Table 6 Global Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 7 Global Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

Table 8 North America Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 9 North America Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)

Table 10 North America Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 11 North America Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

Table 12 US Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 13 US Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)

Table 14 US Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 15 US Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

Table 16 Canada Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 17 Canada Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)

Table 18 Canada Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 19 Canada Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

Table 20 South America Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 21 South America Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)
Table 22 South America Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 23 South America Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

Table 24 Europe Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 25 Europe Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)

Table 26 Europe Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Europe Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

Table 28 Western Europe Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 29 Western Europe Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)

Table 30 Western Europe Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 31 Western Europe Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

Table 32 Eastern Europe Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 33 Eastern Europe Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)

Table 34 Eastern Europe Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 35 Eastern Europe Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

Table 36 Asia Pacific Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 37 Asia Pacific Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)

Table 38 Asia Pacific Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 39 Asia Pacific Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

Table 40 Middle East & Africa Uterine Sarcoma Market by Type, 2017 – 2023, (USD Million)

Table 41 Middle East & Africa Uterine Sarcoma Market by Diagnosis, 2017 – 2023, (USD Million)

Table 42 Middle East & Africa Uterine Sarcoma Market by Treatment, 2017 – 2023, (USD Million)

Table 43 Middle East & Africa Uterine Sarcoma Market by End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Uterine Sarcoma Market

Figure 3 Segmentation Market Dynamics for Global Uterine Sarcoma Market

Figure 4 Global Uterine Sarcoma Market Share, by Type 2016
Figure 32 Koninklijke Philips N.V.: Key Financials
Figure 33 Koninklijke Philips N.V.: Segmental Revenue
Figure 34 Koninklijke Philips N.V.: Geographical Revenue
Figure 35 Siemens Healthcare Private Limited: Key Financials
Figure 36 Siemens Healthcare Private Limited: Segmental Revenue
Figure 37 Siemens Healthcare Private Limited: Geographical Revenue